Table 1

Characteristics of subjects

HNF1A-MODYAutoimmune diabetesType 2 diabetesGCK-MODYNondiabeticP value
n3131624024198
Sex (% male)35.556.355.041.646.5
Age of diagnosis (years)21.4 (14.3–32.0)21.5 (12.2–37.8)34.4 (26.6–44.4)21.3 (11.8–38.6)43.4 (38.4–49.0)<1 × 10−6
Duration of diabetes (years)13.8 (4.0–48.1)11.7 (5.8–23.7)8.5 (2.4–30.8)13.1 (6.8–25.2)0.001
BMI (kg/m2)25.6 (21.0–31.2)25.9 (21.8–30.8)32.7 (26.4–40.4)27.3 (21.7–34.3)26.2 (22.0–31.1)<1 × 10−6
A1C (%)7.1 (5.9–8.5)NA8.0 (6.5–9.9)6.8 (5.6–8.3)NA5 × 10−5
FPG (mmol/l)7.9 (5.2–11.8)NA8.3 (5.6–12.1)7.7 (5.8–10.3)5.1 (4.7–5.7)<1 × 10−6
% treated with aspirin16.17.528.112.500.002§
% treated with statin22.629.763.88.31.03 × 10−6§
Median hs–CRP (mg/l) (includes all values)*0.19 (1.54)0.92 (3.07)3.25 (8.86)1.25 (3.59)0.63 (2.14)<1 × 10−6#
hs-CRP (mg/l) (hs-CRP<10 mg/l, unadjusted)n = 28 0.20 (0.03–1.14)n = 294 0.58 (0.10–2.75)n = 187 1.33 (0.28–6.14)n = 24 1.01 (0.19–5.33)n = 186 0.48 (0.10–2.42)<1 × 10−6
    P value vs. HNF1A-MODY0.001<1 × 10−60.00040.009
hs-CRP (mg/l) (hs-CRP<10 mg/l, users of aspirin and/or statin excluded)n = 20 0.11 (0.02–0.50)n = 186 0.45 (0.07–2.75)n = 61 1.61 (0.30–8.59)n = 20 0.95 (0.16–5.42)n = 184 0.48 (0.09–2.45)<1 × 10−6
    P value vs. HNF1A-MODY0.001<1 × 10−60.0010.001
hs-CRP (mg/l) (hs-CRP<10 mg/l, adjusted for BMI)n = 28 0.27 (0.15–0.46)n = 294 0.76 (0.64–0.91)n = 187 0.76 (0.60–0.96)n = 24 0.95 (0.47–1.89)n = 186 0.57 (0.46–0.71)<1 × 10−6
    P value vs. HNF1A-MODY0.00040.0010.0050.01
  • Data are geometric mean (SD range) unless otherwise indicated. NA, not available.

  • *Median (interquartile range).

  • ‖Estimated marginal means (95% CI).

  • †Age of sampling for control subjects. P value compares all groups and was calculated by

  • ‡ANOVA,

  • §χ2 test (diabetic groups only), or

  • #Kruskal-Wallis test.